Clinical trial
Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration…
NCT00299507 · Alcon Research, Industry · Completed
Key facts
| NCT number | NCT00299507 |
|---|---|
| Title | Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD) |
| Official title | Anecortave Acetate 15 mg Administered Every 3 Months Versus Anecortave Acetate 15 mg Administered Every 6 Months Versus Anecortave Acetate 30 mg Administered Every 6 Months in Patients With Exudative Age-Related Macular Degeneration (AMD) |
| Lead sponsor | Alcon Research, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Macular Degeneration |
| Intervention type | Drug, Other |
| Interventions | Anecortave Acetate Sterile Suspension, 30 mg/mL, 60 mg/mL, Anecortave Acetate Vehicle |
| Enrollment | 240 |
| Start date | Mar 1, 2005 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Mar 7, 2006 |
| Last update posted | Nov 28, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: